Skip to main content

Advertisement

SpringerLink
Log in

Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism

  • ORIGINAL ARTICLE
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

The treatment strategy for secondary hyperparathyroidism is generally determined empirically with regards to present parathyroid function and serum calcium (Ca) and inorganic phosphate (Pi) levels. More evidence is needed to avoid the aimless continuation of active vitamin D therapy.

Methods

Nondiabetic dialysis patients whose plasma intact parathyroid hormone (iPTH) levels were greater than 300 pg/ml were included in the study. Maxacalcitol was intravenously injected three times a week. The treatment was continued for 48 weeks, unless the iPTH level was reduced to less than 300 pg/ml or unfavorable events occurred. The patients whose plasma iPTH levels were below 300 pg/ml within 48 weeks were defined as those who had been successfully treated.

Results

Findings for 146 patients were analyzed, and 96 patients were successfully treated. Serum Pi levels did not significantly increase during the therapy. The pretreatment plasma iPTH levels and serum Ca levels were lower in the patients who were successfully treated with maxacalcitol. A logistic regression study and classifying by stratum analyses revealed that the pretreatment serum Ca levels and plasma iPTH levels were significantly related to the result of maxacalcitol therapy, while the serum Pi levels were not. Analyses using a receiver-operating characteristic curve revealed that the areas under curves obtained for iPTH and Ca were significantly greater than those obtained for Pi (P < 0.0001).

Conclusions

Serum Ca levels and parathyroid function were correlated with the results of maxacalcitol therapy. Pretreatment serum Pi levels could not predict the result.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. TB Drueke (2002) ArticleTitleTreatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis Nephrol Dial Transplant 17 IssueIDs11 20–2 Occurrence Handle1:CAS:528:DC%2BD38Xptlektrw%3D

    CAS  Google Scholar 

  2. N Fukuda H Tanaka Y Tominaga M Fukagawa K Kurokawa Y Seino (1993) ArticleTitleDecreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients J Clin Invest 92 1436–43 Occurrence Handle1:STN:280:ByyA1cfosl0%3D Occurrence Handle8397225

    CAS  PubMed  Google Scholar 

  3. Y Tominaga S Kohara Y Namii T Nagasaka T Haba K Uchida et al. (1996) ArticleTitleClonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism World J Surg 20 744–50 Occurrence Handle10.1007/s002689900113 Occurrence Handle1:STN:280:BymH38jitFM%3D Occurrence Handle8678945

    Article  CAS  PubMed  Google Scholar 

  4. M Tokumoto K Tsuruya K Fukuda H Kanai S Kuroki H Hirakata (2002) ArticleTitleReduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism Kidney Int 62 1196–207 Occurrence Handle10.1111/j.1523-1755.2002.kid585.x Occurrence Handle1:CAS:528:DC%2BD38XotVSntbw%3D Occurrence Handle12234290

    Article  CAS  PubMed  Google Scholar 

  5. CH Hsu (1997) ArticleTitleAre we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29 641–9 Occurrence Handle1:CAS:528:DyaK2sXivFWqtb4%3D Occurrence Handle9100059

    CAS  PubMed  Google Scholar 

  6. SMDr Moe (2003) ArticleTitleueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product Am J Nephrol 23 369–79 Occurrence Handle10.1159/000073945 Occurrence Handle1:CAS:528:DC%2BD3sXptVWktrY%3D Occurrence Handle14551461

    Article  CAS  PubMed  Google Scholar 

  7. M Fukagawa M Kitaoka H Yi N Fukuda T Matsumoto E Ogata et al. (1994) ArticleTitleSerial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients Nephron 68 221–8 Occurrence Handle1:STN:280:ByqC3s3htFE%3D Occurrence Handle7830860

    CAS  PubMed  Google Scholar 

  8. N Onoda S Kurihara Y Sakurai K Owada E Osono H Adachi et al. (2003) ArticleTitleEvaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology Nephrol Dial Transplant 18 IssueIDs3 34–7 Occurrence Handle10.1093/ndt/gfg1042

    Article  Google Scholar 

  9. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;84:728-32.

    Google Scholar 

  10. Y Nishii T Okano (2001) ArticleTitleHistory of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy)calcitriol (ED-71 Steroids 66 137–46 Occurrence Handle10.1016/S0039-128X(00)00227-0 Occurrence Handle1:CAS:528:DC%2BD3MXhtFehsb4%3D Occurrence Handle11179721

    Article  CAS  PubMed  Google Scholar 

  11. K/DOQI Clinical practice guidelines for bone mineral metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S7–S201

  12. JA Hanley (1989) ArticleTitleReceiver operating characteristic (ROC) methodology: the state of the art Crit Rev Diagn Imaging 29 307–35 Occurrence Handle1:STN:280:BiaA3srhslU%3D Occurrence Handle2667567

    CAS  PubMed  Google Scholar 

  13. JJ Kazama K Kutsuwada K Ataka H Maruyama F Gejyo (2002) ArticleTitleSerum cystatin C reliably detects renal dysfunction in patients with various renal diseases Nephron 91 13–20 Occurrence Handle10.1159/000057599 Occurrence Handle1:CAS:528:DC%2BD38XjvVGht70%3D Occurrence Handle12021514

    Article  CAS  PubMed  Google Scholar 

  14. M Rodriguez AJ Felsenfeld C Williams JA Pederson F Llach (1991) ArticleTitleThe effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients J Am Soc Nephrol 2 1014–20 Occurrence Handle1:STN:280:By2C3czhslM%3D Occurrence Handle1760537

    CAS  PubMed  Google Scholar 

  15. F Malberti B Corradi P Cosci F Calliada D Marcelli E Imbasciati (1996) ArticleTitleLong-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism Am J Kidney Dis 28 704–12 Occurrence Handle1:CAS:528:DyaK28XmvFWjsrk%3D Occurrence Handle9158208

    CAS  PubMed  Google Scholar 

  16. M Yasuda T Akiba H Nihei (2003) ArticleTitleMulticenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients Am J Kidney Dis 41 IssueIDs1 S108–11 Occurrence Handle1:CAS:528:DC%2BD3sXisFamtLk%3D Occurrence Handle12612965

    CAS  PubMed  Google Scholar 

  17. JJ Kazama F Sato K Omori H Hama S Yamamoto H Maruyama et al. (2005) ArticleTitlePretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients Kidney Int 67 1120–5 Occurrence Handle10.1111/j.1523-1755.2005.00178.x Occurrence Handle1:CAS:528:DC%2BD2MXis1Gqsr8%3D Occurrence Handle15698453

    Article  CAS  PubMed  Google Scholar 

  18. M Fukagawa Y Tominaga M Kitaoka T Kakuta K Kurokawa (1999) ArticleTitleMedical and surgical aspects of parathyroidectomy Kidney Int 73 IssueIDs1 S65–9 Occurrence Handle10.1046/j.1523-1755.1999.07309.x Occurrence Handle1:STN:280:DC%2BD3c%2FpvFartg%3D%3D

    Article  CAS  Google Scholar 

  19. CS Ritter JL Finch EA Slatopolsky AJ Brown (2001) ArticleTitleParathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor Kidney Int 60 1737–44 Occurrence Handle10.1046/j.1523-1755.2001.00027.x Occurrence Handle1:CAS:528:DC%2BD3MXotlGnsbo%3D Occurrence Handle11703591

    Article  CAS  PubMed  Google Scholar 

  20. M Rodriguez A Canalejo B Garfia E Aguilera Y Almaden (2002) ArticleTitlePathogenesis of refractory secondary hyperparathyroidism Kidney Int 80 IssueIDs1 S155–60 Occurrence Handle10.1046/j.1523-1755.61.s80.26.x Occurrence Handle1:CAS:528:DC%2BD3sXhs1Wgsro%3D

    Article  CAS  Google Scholar 

  21. E Slatopolsky A Brown A Dusso (2001) ArticleTitleRole of phosphorus in the pathogenesis of secondary hyperparathyroidism Am J Kidney Dis 37 IssueIDs1 S54–7 Occurrence Handle1:CAS:528:DC%2BD3MXltFKquw%3D%3D Occurrence Handle11158862

    CAS  PubMed  Google Scholar 

  22. A Jara C Chacon AJ Felsenfeld (2002) ArticleTitleHyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats Nephron 92 883–8 Occurrence Handle10.1159/000065454 Occurrence Handle1:CAS:528:DC%2BD38Xot1Smt7o%3D Occurrence Handle12399635

    Article  CAS  PubMed  Google Scholar 

  23. T Akizawa M Suzuki T Akiba Y Nishizawa Y Ohashi E Ogata et al. (2002) ArticleTitleLong-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study Nephrol Dial Transplant 17 IssueIDs10 28–36 Occurrence Handle1:CAS:528:DC%2BD38XptlektLo%3D

    CAS  Google Scholar 

  24. Y Tsukamoto M Hanaoka T Matsuo T Saruta M Nomura Y Takahashi (2000) ArticleTitleEffect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism Am J Kidney Dis 35 458–64 Occurrence Handle1:CAS:528:DC%2BD3cXhvFGiu7s%3D Occurrence Handle10692271

    CAS  PubMed  Google Scholar 

  25. JJ Kazama K Omori N Higuchi N Takahashi Y Ito H Maruyama et al. (2004) ArticleTitleIntact PTH assay overestimates 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism Nephrol Dial Transplant 19 892–7 Occurrence Handle10.1093/ndt/gfh038 Occurrence Handle1:CAS:528:DC%2BD2cXitl2ksrs%3D Occurrence Handle15031346

    Article  CAS  PubMed  Google Scholar 

  26. S Doi N Yorioka K Usui K Shigemoto S Harada (2003) ArticleTitleEffect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients Intern Med 42 955–9 Occurrence Handle1:CAS:528:DC%2BD2cXis12itw%3D%3D Occurrence Handle14606707

    CAS  PubMed  Google Scholar 

  27. JL Finch AJ Brown N Kubodera Y Nishii E Slatopolsky (1993) ArticleTitleDifferential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism Kidney Int 43 561–6 Occurrence Handle1:CAS:528:DyaK3sXktVSlu7Y%3D Occurrence Handle8455354

    CAS  PubMed  Google Scholar 

  28. M Hirata K Katsumata K Endo N Fukushima H Ohkawa M Fukagawa (2003) ArticleTitleIn subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiova-scular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3 Nephrol Dial Transplant 18 1770–6 Occurrence Handle10.1093/ndt/gfg296 Occurrence Handle1:CAS:528:DC%2BD3sXnvF2lu7w%3D Occurrence Handle12937223

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-751 Asahimachi-dori, Niigata, 951-8510, Japan

    Yuko Oyama, Junichiro James Kazama, Kentaro Omori, Noboru Higuchi, Shigemi Kameda, Suguru Yamamoto, Yumi Ito, Hiroki Maruyama, Ichiei Narita & Fumitake Gejyo

Authors
  1. Yuko Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junichiro James Kazama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kentaro Omori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noboru Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigemi Kameda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suguru Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yumi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroki Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ichiei Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fumitake Gejyo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fumitake Gejyo.

About this article

Cite this article

Oyama, Y., Kazama, J., Omori, K. et al. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 9, 142–147 (2005). https://doi.org/10.1007/s10157-005-0342-2

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-005-0342-2

Key words

Search

Navigation